Xuesong Wang
Onderzoeker
- Naam
- Dr. X. Wang
- Telefoon
- 071 5276225
- x.wang@lacdr.leidenuniv.nl
Meer informatie is beschikbaar op de Engelse profielpagina.
Onderzoeker
- Wiskunde en Natuurwetenschappen
- Leiden Academic Centre for Drug Research
- LACDR/Toxicology
- Hollander L.S. den, Béquignon O.J.M., Wang X., Wezel K. van, Broekhuis J.D., Gorostiola Gonzalez M., Visser K.E. de, IJzerman A.P., Westen G.J.P. van & Heitman L.H. (2023), Corrigendum to "Impact of cancer-associated mutations in CC chemokine receptor 2 on receptor function and antagonism" [Biochem. Pharmacol. 208 (2023) 115399], Biochemical Pharmacology 209: 115540 (115450).
- Wang X., Jespers W., Waal J.J. de, Wolff K.A.N., Uden L. van, IJzerman A.P., Westen G.J.P. van & Heitman L.H. (2022), Cancer-related somatic mutations alter adenosine A1 receptor pharmacology: a focus on mutations in the loops and C- terminus, The FASEB Journal 36(6): e22358.
- Wang X., Jespers W., Wolff K.A.N., Buytelaar J., IJzerman A.P., Westen G.J.P. van & Heitman L.H. (2022), Cancer-related somatic mutations in transmembrane helices alter adenosine A1 receptor pharmacology, Molecules 27(12): 3742.
- Beerkens B.L.H., Wang X., Avgeropoulou M., Adistia L.N., Veldhoven J.P.D. van, Jespers W., Liu R., Heitman L.H., IJzerman A.P. & Es D. van der (2022), Development of subtype-selective covalent ligands for the adenosine A2B receptor by tuning the reactive group, RSC Medicinal Chemistry 13(7): 850-856.
- Wang X. (20 september 2022), The good? The bad? The mutant! : Characterization of cancer-related somatic mutations and identification of a selectivity hotspot in adenosine receptor (Dissertatie. Leiden Academic Centre for Drug Research (LADCR), Faculty of Science, Leiden University). Promotor(en): IJzerman A.P., Heitman L.H. & Westen G.J.P. van.
- Feng C.L., Wang X., Jespers W., Liu R., Zamarbide Losada S.D., Gorostiola Gonzalez M., Westen G.J.P. van, Danen E.H.J. & Heitman L.H. (2022), Cancer-associated mutations of the adenosine A2A receptor have diverse influences on ligand binding and receptor functions, Molecules 27(15): 4676.
- Bongers B.J., Gorostiola González M., Wang X., Vlijmen H. van, Jespers W., Gutiérrez-de-Terán H., Ye K., IJzerman A.P., Heitman L.H. & Westen G.J.P. van (2022), Pan-cancer functional analysis of somatic mutations in G protein-coupled receptors, Scientific Reports 12(1): 21534.
- Wang X., Westen G.J.P. van, IJzerman A.P. & Heitman L.H. (2022), G protein-coupled receptors and their mutations in cancer: a focus on adenosine receptors. In: Gilchrist A. (red.), GPCRs as therapeutic targets: John Wiley & Sons. 631-676.
- Hollander L.S. den, Béquignon O.J.M., Wang X., Wezel K. van, Broekhuis J., Gorostiola González M., Visser K.E. de, IJzerman A.P., Westen G.J.P. van & Heitman L.H. (2022), Impact of cancer-associated mutations in CC chemokine receptor 2 on receptor function and antagonism, Biochemical Pharmacology 208: 115399.
- Wang X., Westen G.J.P. van, Heitman L.H. & IJzerman A.P. (2021), G protein-coupled receptors expressed and studied in yeast. The adenosine receptor as a prime example, Biochemical Pharmacology 187: 114370.
- Wang X., Jespers W., Prieto-Díaz R., Majellaro M., IJzerman A.P., Westen G.J.P. van, Sotelo E. & Heitman L.H. (2021), Identification of V6.51L as a selectivity hotspot in stereoselective A2B adenosine receptor antagonist recognition, Scientific Reports 11: 14171.
- Wang X. Jespers W. Bongers B.J. Habben Jansen M.C.C. Stangenberger C.M. Dilweg M.A. Gutiérrez-de-Terán H. IJzerman A.P. Heitman L.H. Westen G.J.P. van (2020), Characterization of cancer-related somatic mutations in the adenosine A2B receptor, European Journal of Pharmacology 880: 173126.
- Doornbos M.L.J., Wang X., Vermond S.C., Peeters L., Pérez-Benito L., Trabanco A.A., Lavreysen H., Cid J.M., Heitman L.H., Tresadern G. & IJzerman A.P. (2019), Covalent Allosteric Probe for the Metabotropic Glutamate Receptor 2: Design, Synthesis, and Pharmacological Characterization, Journal of Medicinal Chemistry 62(1): 223-233.